Published in Br J Clin Pharmacol on March 01, 1992
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob Agents Chemother (2007) 1.35
Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir. Antimicrob Agents Chemother (2004) 1.13
Didanosine population pharmacokinetics in West African human immunodeficiency virus-infected children administered once-daily tablets in relation to efficacy after one year of treatment. Antimicrob Agents Chemother (2009) 0.84
Transfer of dideoxyinosine across the human isolated placenta. Br J Clin Pharmacol (1994) 0.81
Effect of fluconazole on pharmacokinetics of 2',3'-dideoxyinosine in persons seropositive for human immunodeficiency virus. Antimicrob Agents Chemother (1995) 0.81
Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine. Antimicrob Agents Chemother (2004) 0.75
Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. Antimicrob Agents Chemother (1998) 0.75
Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides. Proc Natl Acad Sci U S A (1986) 6.63
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med (1990) 2.52
Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity. Biochem Pharmacol (1987) 2.10
Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther (1990) 1.87
Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol (1987) 1.57
Altered erythrocyte nucleotide patterns are characteristic of inherited disorders of purine or pyrimidine metabolism. Clin Chim Acta (1988) 1.41
Metabolic pathways for the activation of the antiretroviral agent 2',3'-dideoxyadenosine in human lymphoid cells. J Biol Chem (1988) 1.32
Purine nucleoside phosphorylase. Microheterogeneity and comparison of kinetic behavior of the enzyme from several tissues and species. Biochemistry (1975) 1.25
Incorporation of analog purine nucleosides into the formed elements of human blood: erythrocytes, platelets, and lymphocytes. Ann N Y Acad Sci (1975) 1.13
Chemotherapy of human immunodeficiency virus infections: current practice and future prospects. J Infect Dis (1990) 1.01
Purine nucleoside phosphorylase from human erythrocytes. Methods Enzymol (1978) 0.94
High-performance liquid chromatographic method for analysis of 2',3'-dideoxyinosine in human body fluids. J Chromatogr (1990) 0.86
The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS (1998) 2.16
Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS (1997) 1.65
Evaluation of Committee on Safety of Medicines yellow card reports on oral contraceptive-drug interactions with anticonvulsants and antibiotics. Br J Clin Pharmacol (1988) 1.56
In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. Br J Clin Pharmacol (1988) 1.44
Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br J Clin Pharmacol (1998) 1.25
Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. AIDS (1999) 1.21
Uptake of genetic testing for cancer predisposition. J Med Genet (1997) 1.16
Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol (1991) 1.15
How climate change might influence the starvation-predation risk trade-off response. Proc Biol Sci (2009) 1.07
Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. Br J Clin Pharmacol (1989) 1.03
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br J Clin Pharmacol (1994) 0.99
Azoles, allylamines and drug metabolism. Br J Dermatol (1992) 0.97
P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. J Antimicrob Chemother (2002) 0.93
Sulphaphenazole and drug oxidation in man. Br J Clin Pharmacol (1983) 0.92
An interpretation of the observed polymorphism of potato yellow dwarf virus. Virology (1968) 0.90
The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation. Pharmacogenetics (1999) 0.89
Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes. J Steroid Biochem Mol Biol (1991) 0.89
Plasma concentrations of 3-keto-desogestrel after oral administration of desogestrel and intravenous administration of 3-keto-desogestrel. Contraception (1987) 0.89
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. Br J Clin Pharmacol (1995) 0.87
Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat. Br J Pharmacol (1984) 0.86
Inhibition of tolbutamide metabolism by substituted imidazole drugs in vivo: evidence for a structure-activity relationship. Br J Pharmacol (1985) 0.86
Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications. Br J Clin Pharmacol (1993) 0.85
Studies on a virus isolated from Gonometa podocarpi (Lepidoptera:Lasiocampidae). J Gen Virol (1973) 0.83
Use of MRI and audiological tests in presymptomatic diagnosis of type 2 neurofibromatosis (NF2). J Med Genet (2000) 0.82
In vitro transcription of wound tumor virus RNA by virion-associated RNA transcriptase. Virology (1977) 0.82
A G1 cell cycle arrest induced by ligands of the reovirus type 3 receptor is secondary to inactivation of p21ras and mitogen-activated protein kinase. DNA Cell Biol (1999) 0.80
Chromatographic and immunochemical approaches to the analysis of the HIV protease inhibitor saquinavir in plasma. Anal Biochem (2000) 0.80
Actions of intravenous magnesium on ventricular arrhythmias caused by acute myocardial infarction. J Pharmacol Exp Ther (1991) 0.78
The ribonucleic acid of potato yellow dwarf virus. Virology (1972) 0.77
Pharmacokinetics and protein binding of 3-ketodesogestrel and gestodene in the serum of women during 6 cycles of treatment with two low dose oral contraceptives. Adv Contracept (1993) 0.77
Single dose primaquine has no effect on paracetamol clearance. Eur J Clin Pharmacol (1987) 0.77
Delayed diaphragmatic rupture presenting with acute gastric volvulus. Ann R Coll Surg Engl (2014) 0.75
Managing capital assets. N Z Health Hospital (1989) 0.75
Potential problems with aqueous steroid solutions. J Pharm Pharmacol (1983) 0.75
Science and democracy: historical reflections on present discontents. Minerva (1997) 0.75
Dr. Macleod on the Statistics of Rheumatism. Prov Med J Retrosp Med Sci (1842) 0.75
The in-vitro mucosal conjugation of ethinyloestradiol and the bioavailability of oral contraceptive steroids in patients with treated and untreated coeliac disease. Aliment Pharmacol Ther (1992) 0.75
Cyclosporin metabolites and neurotoxicity. Lancet (1989) 0.75
The effect of some benzimidazoles on the disposition of antipyrine and tolbutamide from the rat isolated perfused liver. J Pharm Pharmacol (1985) 0.75
The relative bioavailability of levonorgestrel and ethinylestradiol when administered in tablet and capsule form. Contraception (1987) 0.75
Root and shoot growth, assimilate partitioning and cell proliferation in roots of Sitka spruce (Picea sitchensis) grown in filtered and unfiltered chambers. Environ Pollut (1996) 0.75
Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients. AIDS (1998) 0.75